Theravance Biopharma
- Country
- Ownership
- -
- Employees
- 99
- Market Cap
- -
- Introduction
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded i...
Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 36
- Registration Number
- NCT03555617
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Drug-Drug Interaction (DDI) Study for TD-9855
- Conditions
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 41
- Registration Number
- NCT03432793
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 20
- Registration Number
- NCT03408470
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)
- Conditions
- Interventions
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 32
- Registration Number
- NCT03103412
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 40
- Registration Number
- NCT02954263
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Single Ascending Dose Study of TD-1439 in Healthy Subjects
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 66
- Registration Number
- NCT02903095
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
TD-1473 for Active Ulcerative Colitis (UC)
- Conditions
- Interventions
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 40
- Registration Number
- NCT02818686
- Locations
- 🇷🇴
Theravance Biopharma Investigational Site, Bucharest, Romania
Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects
- First Posted Date
- 2016-03-16
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 50
- Registration Number
- NCT02709928
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
- Conditions
- Interventions
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 34
- Registration Number
- NCT02705755
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site, Dallas, Texas, United States
A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 6
- Registration Number
- NCT02663089
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom